1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


TABLE 
Demographics and imaging results
Patient No./Sex/Age (y)Histologic DiagnosisTumor LocationUSPIOIron UptakeT1 Signal Intensity ChangeT2 Signal Intensity Change
1/F/48Metastatic large cell carcinomaCerebellumFerumoxides−−−
2/M/46Anaplastic oligodendragliomaR temporoparietalFerumoxides+*+−
3/F/53MeningiomaL frontalFerumoxides−−−
4/M/54Gliblastoma multiformeL thalamus, parietalFerumoxtran-10+++
5/M/55Anaplastic oligodendragliomaL temporalFerumoxtran-10+†++
6/M/54OligodendrogliomaL frontotemporalFerumoxtran-10−−−
7/F/47HamartomaL temporalFerumoxtran-10+*+−
8/F/30MedulloblastomaCerebellumFerumoxtran-10+†++
9/M/58Anaplastic oligodendragliomaR temporoparietalFerumoxtran-10+†++
10/M/55Squamous cell carcinomaNasopharynx with skull base invasionFerumoxtran-10+++
11/M/50Squamous cell carcinomaNasopharynx with skull base invasionFerumoxtran-10+++
12/F/42MeningiomaL petroclivalFerumoxtran-10+†++
13/M/57OligodendrogliomaR parietalFerumoxtran-10−−−
14/M/55Anaplastic gliomaL temporalFerumoxtran-10+*+−
15/F/54Glioblastoma multiformeR temporoparietalFerumoxtran-10+++
16/F/66Glioblastoma multiformeR frontalFerumoxtran-10+†++
17/F/57Anaplastic oligodendragliomaR frontalFerumoxtran-10+†++
18/M/54Pituitary adenomaIntra- and suprasellarFerumoxtran-10+++
19/M/39Glioblastoma multiformeL fronto-opercularFerumoxtran-10+++
20/M/46Anaplastic oligodendragliomaR posterior temporalFerumoxtran-10+†++
  • Note.—L indicates left; R, right; +, yes; −, no.
  • * Iron accumulation was only minimal compared with gadolinium enhancement.
  • † Ferumoxtran enhancement as measured with ROI (see Methods) was regionally more prominent than gadolinium enhancement.